A paper recently published by various authors in Florida, USA, recently detailed the incredible response of three cases of severe, long-term COVID-19 patients (two women and one overweight diabetic man) who experienced a rapid return to full health after receiving monoclonal antibody (casirivimab/imdevimab) infusions. Their severe symptoms, including fatigue, muscle aches, brain fog, etc. disappeared within a week of the infusion. The Healthrising blog discussed this paper in their entry of 29/11/23.
The antibody treatment was originally given in hopes of preventing their conditions from worsening, not with the expectation that it would lead to dramatic improvements. So the recoveries came as a major surprise to the medical team and patients.
The authors speculate on several mechanisms by which the antibody infusions could be eliminating remaining virus or dysfunctional immune factors, allowing patients’ health to be restored. They suggest implications for treating other post-viral illnesses like ME/CFS.
However, the limitations of this small case series are emphasized. Larger, controlled studies are needed to truly assess the treatment’s efficacy and mechanisms. Still, the rapid patient improvements were striking.
The authors call for further research, ideally large observational studies of long COVID patients receiving these monoclonal antibodies, to better evaluate the potential. They report knowing of more similar cases beyond these initial three.
In summary, this early case report presents intriguing findings that monoclonal antibody treatment led to full recoveries in severe long COVID patients. But significantly more evidence is required to confirm the treatment’s efficacy and generalizability. The implications for ME/CFS and post-viral illnesses remain speculative at this point.